Drug/lab interactions: Gosrelin suppresses the pitutary-gonadal system .Therefore, diagnostic tests of pituitary -gonadotropic and gonadal functions conducted during treatment and until resumption of menses may show misleading results

Hot flushes, Sexual dysfunction, Decreased erections, Lower urinary tract symptoms, Lethargy, Pain, Edema, Upper respiratory infection, Rash, Sweating, Anorexia, Achronic obstructive pulmonary disease, Dizziness, Insomnia, Nausea.

Pregnancy, lactation, non diagnosed vaginal bleeding

Special precautions:

Prostatic and breast cancer worsening, hypercalcemia, lipids levels, bone mineral density changes, antibody formation.

Indications:

Prostatic acncer, endometriosis

Dosage: Monthly (3.6mg) implant- administer SC every 28 days into upper abdominal wall. Local anesthesia may be used before injection

Pharmacology:

Goserelin acetate is a synthetic decapeptide analog of luteinizing hormone-releasing hormone. It acts as a potent inhibitor of pituitary gonaddotropin secretion when administerd in biodegradable formulation

Pharmacokinetics:

Peak serum levels are acheived 12 to 15 days after SC administration in males. Goserelin implant is absorbed at a much slower rate initially for the first 8 days, and there is more rapid and continuous absorption for the remainder of the 28 day dosing period.

Pregnancy:

Do not use in women who are or who may become pregnant while receiving the drug.

Lactation:

Discontinue the drug before breast feeding